FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 05/2025”.
The Monitor is a month-to-month revealed overview of enterprise capital tendencies within the US Healthcare & Life Sciences sector.
As of the tip of Could 2025 we recognized the next present VC tendencies in the US:
- Complete Healthcare & Life Sciences funding reached EUR 15,796m (-9% vs. 2024)
- Biotech/Pharma obtained 40% of the full funding quantity (EUR 6,357m) with oncology being the main indication (27%)
- In Could Neuralink secured the highest transaction quantity with EUR 576m, adopted by Pathos with EUR 327m and Lumicell with EUR 176m
- Illumina (United States) is probably the most energetic investor (by deal quantity in 2025), adopted by Regeneron Prescription drugs (United States) and Bain Capital Life Sciences (United States)
To entry the total report, please click on right here.
